Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin® litigation
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Previous studies have documented strategies to promote off-label use of drugs using journal publications and other means. Few studies have presented internal company communications that discussed financial reasons for manipulating the scholarly record related to off-label indications. The objective of this study was to build on previous studies to illustrate implementation of a publication strategy by the drug manufacturer for four off-label uses of gabapentin (Neurontin®, Pfizer, Inc.): migraine prophylaxis, treatment of bipolar disorders, neuropathic pain, and nociceptive pain. Methods: We included in this study internal company documents, email correspondence, memoranda, study protocols and reports that were made publicly available in 2008 as part of litigation brought by consumers and health insurers against Pfizer for fraudulent sales practices in its marketing of gabapentin (see http://pacer.mad.uscourts.gov/dc/cgi-bin/recentops.pl?filename=saris/pdf/ucl%20opinion.pdf for the Court’s findings). We reviewed documents pertaining to 20 clinical trials, 12 of which were published. We categorized our observations related to reporting biases and linked them with topics covered in internal documents, that is, deciding what should and should not be published and how to spin the study findings (re-framing study results to explain away unfavorable findings or to emphasize favorable findings); and where and when findings should be published and by whom. Results: We present extracts from internal company marketing assessments recommending that Pfizer and Parke-Davis (Pfizer acquired Parke-Davis in 2000) adopt a publication strategy to conduct trials and disseminate trial findings for unapproved uses rather than an indication strategy to obtain regulatory approval. We show internal company email correspondence and documents revealing how publication content was influenced and spin was applied; how the company selected where trial findings would be presented or published; how publication of study results was delayed; and the role of ghost authorship. Conclusions: Taken together, the extracts we present from internal company documents illustrate implementation of a strategy at odds with unbiased study conduct and dissemination. Our findings suggest that Pfizer and Parke-Davis’s publication strategy had the potential to distort the scientific literature, and thus misinform healthcare decision-makers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147 · cited 1×
“There is now ample evidence that selective reporting of study results, based on the strength and direction of findings (reporting biases), is widely practiced by the pharmaceutical industry [5,6].”
BackgroundChan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845 · cited 1×
“Indeed, reporting biases have been documented in trials sponsored by both industry and not-for-profit entities [45,46].”
BackgroundThe Existence of Publication Bias and Risk Factors for Its Occurrence
Dickersin, K. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440100097014 · Cited by 1,417 · cited 1×
“We assessed the documents for appearance of the following reporting biases: (a) publication bias (that is, publishing a study report based on strength and direction of findings), (b) outcome reporting bias (that is, selective reporting of outcomes based on the strength and direction of findings), (c) location bias (th…”
MethodSelf-citationDissemination and publication of research findings: an updated review of related biases
Song, F., Parekh, Hooper, L., Loke, Y., Ryder, J., Sutton, A., Hing, C., Kwok, C., Pang, C., & Harvey, I. (2010) · Health Technology Assessment · doi:10.3310/hta14080 · Cited by 1,039 · cited 2×
“There is now ample evidence that selective reporting of study results, based on the strength and direction of findings (reporting biases), is widely practiced by the pharmaceutical industry [5,6].”
BackgroundMethodBoutron, I. (2010) · JAMA · doi:10.1001/jama.2010.651 · Cited by 842 · cited 2×
“Our definition for spin extends work previously done by others on this topic, which used only published literature and focused on trials with statistically non-significant findings [13].”
BackgroundAls-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. L. (2003) · JAMA · doi:10.1001/jama.290.7.921 · Cited by 746 · cited 1×
“Most clinical trials testing the effectiveness of drugs are sponsored by two types of entities: the pharmaceutical industry and not-for-profit organizations [49-51], such as the National Institutes of Health in the U.”
BackgroundPrevalence of Articles With Honorary Authors and Ghost Authors in Peer-Reviewed Medical Journals
Flanagin, A. (1998) · JAMA · doi:10.1001/jama.280.3.222 · Cited by 553
Epidemiology and reporting of randomised trials published in PubMed journals
Chan, A.-W., & Altman, D. G. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71879-1 · Cited by 474
Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research
Chan, A.-W. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041086 · Cited by 444
Ghosts in the Machine: Publication Planning in the Medical Sciences
Sismondo, S. (2009) · Social Studies of Science · doi:10.1177/0306312708101047 · Cited by 297
Cited by
‘Spin’ in published biomedical literature: A methodological systematic review
Chiu, K., Grundy, Q., & Bero, L. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2002173 · Cited by 317
Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy
Mayo-Wilson, E., Li, T., Fusco, N., Bertizzolo, L., Canner, J. K., Cowley, T., Doshi, P., Ehmsen, J., Gresham, G., Guo, N., et al. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.07.014 · Cited by 108
Self-citationThe promise and perils of industry‐funded science
Holman, B., & Elliott, K. C. (2018) · Philosophy Compass · doi:10.1111/phc3.12544 · Cited by 88
Lockyer, S., Hodgson, R., Dumville, J. C., & Cullum, N. (2013) · Trials · doi:10.1186/1745-6215-14-371 · Cited by 66
“Vera-Badillo and colleagues [6], focusing on clinical trials for women with breast cancer, reported that 59% (54/92) of studies that found a statistically nonsignificant difference for the primary outcome result contained spin in either the abstract or concluding statement, while Vedula and colleagues [7] observed tha…”
Kasenda, B., von Elm, E., You, J. J., Blümle, A., Tomonaga, Y., Saccilotto, R., Amstutz, A., Bengough, T., Meerpohl, J. J., Stegert, M., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002046 · Cited by 33
Metadata
- Authors
- Vedula, S. S., Goldman, P. S., Rona, I. J., Greene, T. M., & Dickersin, K.
- Venue
- Trials
- Published
- 2012-08-13
- Volume
- 13
- Issue
- 1
- Pages
- 136-136
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2136665212
- Cited by
- 46
- References
- 10
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin® litigation. https://app.cochat.ai/papers/10.1186/1745-6215-13-136
- The paper
- Vedula, S. S., Goldman, P. S., Rona, I. J., Greene, T. M., & Dickersin, K. (2012). Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin® litigation. Trials. https://doi.org/10.1186/1745-6215-13-136
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.